Research Article

Association between Interleukin-10 Gene Polymorphisms and Behcet’s Disease Susceptibility: Evidence from a Meta-Analysis

Xue-Feng Li,1 Zhi-Zhen Huang,2 Yuan-Yuan Hu,2 Yu-Ming Niu1,1,2 and Jun-Wei Cai1,2

1Department of Endocrinology, Hubei Key Laboratory of Embryonic Stem Cell Research, Taihe Hospital, Hubei University of Medicine, Shiyuan 442000, China
2Department of Stomatology, Evidence-Based Medicine and Clinical Research, Hubei Key Laboratory of Embryonic Stem Cell Research, Taihe Hospital, Hubei University of Medicine, Shiyuan 442000, China

Correspondence should be addressed to Yu-Ming Niu; niuyuming@yeah.net and Jun-Wei Cai; caijunwei001@126.com

Received 28 November 2019; Revised 6 May 2020; Accepted 19 May 2020; Published 19 June 2020

Academic Editor: Huaxi Xu

Copyright © 2020 Xue-Feng Li et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Epidemiological studies have demonstrated that interleukin-10 (IL-10) polymorphisms may be associated with the development of Behcet’s disease (BD). However, the published results were inconsistent. Therefore, this meta-analysis was conducted to derive a more precise relationship between IL-10 polymorphisms and BD susceptibility. Online databases (PubMed, Embase, Science Citation Index (SCI), CNKI, and WanFang) were searched to identify eligible studies. Odds ratio (OR) and a 95% confidence interval (CI) were applied to assess the relationship strength between IL-10 -1082A>C polymorphisms and BD susceptibility. Publication bias, sensitivity, and cumulative analyses were conducted to measure the robustness of our findings. Finally, fifteen articles (36 independent case-control studies) involving 5,971 patients and 8,913 controls were included. Overall, significant associations between -819T>C polymorphisms and BD risk were observed in the total population (C vs. T: OR = 0.72, 95%CI = 0.67-0.77, P < 0.01, I² = 36.6%; TC vs. TT: OR = 0.73, 95% CI = 0.66-0.80, P < 0.01, I² = 23.0%; CC vs. TT: OR = 0.52, 95%CI = 0.39-0.70, P < 0.01, I² = 53.7%; TC+CC vs. TT: OR = 0.67, 95%CI = 0.61-0.71, P < 0.01, I² = 22.1%; and CC vs. TT+TC: OR = 0.66, 95%CI = 0.53-0.82, P < 0.01, I² = 57.8%). Moreover, the IL-10 -592 A>C polymorphism and the ACC haplotype exhibited a significant, protective effect against BD susceptibility. In summary, our meta-analysis suggested that IL-10 gene polymorphisms may play a salient role for BD development.

1. Introduction

Behcet’s disease (BD) is a chronic polygenic autoimmune disorder, characterized by multiple affected body parts, with common symptoms including recurrent oral ulcers, ocular inflammation, genital ulcers, and skin lesions [1, 2]. In addition, other organs, such as the musculoskeletal, gastrointestinal, central nervous, and pulmonary systems may be affected and present some clinical manifestations [3]. Today, the most authoritative diagnostic criteria were made according to the criteria of the International Study Group of BD: oral ulceration plus any two genital ulcerations, typical defined eye lesions, typical defined skin lesions, or a positive pathergy test [4]. BD is most common in Asian countries, such as China and Japan (East Asian (EA)), as well as in the Middle East (ME) around the regions of the Old Silk Road, such as Turkey and Iran [5]. Epidemiological studies have shown that BD has the highest prevalence in the population of Jordan, a slightly lower prevalence in East Asian countries, and the lowest prevalence in Western countries [6-9]. Pathologically, the lesions always impair arterioles, venules, and microvessels, resulting in the development of microvasculitis with vascular wall necrosis, dilation, and rupture. To date, the etiology and pathogenesis of BD have not been elucidated; however, environmental risks, immunological aberrations, and multiple genetic factors are considered risk factors that can increase susceptibility to BD [10, 11]. Interleukin-10 has been proven to be an important cytokine-suppressing, autoimmune and inflammatory response factor. IL-10 may inhibit the antigen-presenting process by downregulating the expression of HLA molecules on the surface of a cell and suppressing the expression of multiple
proinflammatory cytokines, such as TNF-α, IL-1, IL-6, and IL-8, by inhibiting T cells. IL-10 is secreted by T lymphocytes (mainly Th2 subsets), B lymphocytes, NK cells, monocytes, and macrophages and is involved in the pathogenesis of BD [12, 13].

A number of studies have indicated that the aberrant expression of IL-10 might lead to an inflammatory state that is more susceptible to BD [14, 15]. A recent genome-wide association study (GWAS) demonstrated that a common polymorphic locus of rs1518111 in IL-10 may cause individuals to have a predisposition to BD [16]. The three most common single nucleotide polymorphisms (SNPs) were in the promoter of IL-10 with loci of -1082A>G (rs1800896), -819T>C (rs1800871), and -592A>C (rs1800872), which could influence the gene transcription and expression by changing the promoter binding site, resulting in differing susceptibility of individuals to the disease. To date, a large number of studies have been published on the association between IL-10 polymorphisms and BD susceptibility.

In 2013, Liang et al. conducted the first meta-analysis based on four case-control studies, exploring the potential association between the three IL-10 polymorphisms mentioned and BD risk [17]. In the last six years, new studies have been published on this topic, but the results are still inconsistent and remain inconclusive. Therefore, we conducted an updated meta-analysis to clarify the genetic association between the -1082A>G (rs1800896), -819T>C (rs1800871), and -592A>C (rs1800872) polymorphisms of the IL-10 gene and the risk of BD.

2. Materials and Methods

This meta-analysis was conducted according to the guidelines of the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement [18]. All included data were based on published studies, and no ethical issues were involved.

2.1. Search Strategy. Three English databases (PubMed, Embase, and Science Citation Index (SCI)) and two Chinese databases (CNKI and WanFang) were searched with the following terms from their inception up to May 1, 2019: “Interleukin 10,” “IL-10,” “rs1800896,” “rs1800871,” “rs1800872,” “polymorphism,” “variant,” “mutation,” “Behcet’s disease,” and “BD.” Some relevant papers cited within retrieved articles were also reviewed through manual searches. The following search strategy was used (PubMed for example):

(#1) Interleukin 10
(#2) IL-10
(#3) rs1800896
(#4) rs1800871
(#5) rs1800872
(#6) #1 OR #2 OR #3 OR #4 OR #5
(#7) Polymorphism

2.2. Eligibility Criteria. All selected studies met the following criteria: (1) case-control design was employed; (2) some polymorphisms of the IL-10 gene was reported; (3) sufficient data on genotypes of each polymorphism locus were provided to calculate the odds ratios (ORs) and 95% confidence intervals (CIs); (4) the most recent or largest sample sizes were selected when multiple publications were repeatedly reported with the same theme; and (5) the articles were written only in English and Chinese. The studies were excluded if they were (1) letters, reviews, or conference reports; (2) duplicate reports with the same theme and samples; (3) animal models or cell line studies; or (4) studies without sufficient data.

2.3. Data Extraction. Two independent investigators (LXF and HZZ) reviewed the articles and extracted the following information: name of first author in each study, year of publication, study country or region where the study was conducted, ethnicity of research population, design of the control, sample sizes of patients with BD and controls, frequency genotype of distribution data, and genotyping method used. Disagreements were settled through discussion.

2.4. Quality Assessment. Each study included was evaluated via risk assessment of bias by two authors, LXF and HZZ, according to the modified Newcastle-Ottawa Quality Assessment Scale [19]. The score was assigned on the basis of five parameters (representativeness of cases, source of controls, Hardy-Weinberg’s equilibrium (HWE) in controls, genotyping examination, and association assessment) and ranked from zero to 11 points. Studies with a score of at least 7 were considered to be of high quality (Table 1).

2.5. Statistical Analysis. The pooled ORs with 95% CIs were used to assess the strength of the associations between the IL-10 gene polymorphisms and BD risk. For example, the genetic models of the -1082A>G (rs1800896) polymorphisms were examined: allele contrast (G vs. A), codominant models (heterozygote model: AG vs. AA; homozygote model: GG vs. AA), dominant model (AG+GG vs. AA), and recessive model (GG vs. AA+AG). Similar genetic models were also examined with the other polymorphic loci (-819T>C (rs1800871) and -592A>C (rs1800872)). Heterogeneity was investigated by Cochran’s χ²-based Q-statistic among the included studies [20]. A fixed-effect model (Mantel-Haenszel’s method) was used to evaluate the results if heterogeneity was not significant (I² < 40%) [21]. Otherwise, a random-effects model (DerSimonian and Laird’s method) was used [22]. Subgroup
analyses were performed according to HWE status, ethnic differences, and control design and genotyping methods. Cumulative analyses were conducted to test the changing trends in the results, and sensitivity analyses were conducted to test the robustness of the original results with the published studies which were added gradually. Publication bias testing was conducted with Egger’s bias test and Begg’s funnel plots [23, 24]. Statistical analysis was performed using STATA version 14.0 (Stata Corporation, College Station, TX, USA), and P values < 0.05 were considered to be significant.

3. Results

3.1. Study Characteristics. A total of 224 potential articles were retrieved from the databases at the first step. During the subsequent screening and selection steps of duplicate checks, title and abstract checks, and text reviews, 209 articles were excluded according to the eligibility criteria. Finally, fifteen articles (36 independent case-control studies) involving 5,971 patients and 8,913 controls were included in this meta-analysis (Figure 1) [5, 13, 25–37]. Of these studies, nine case-control studies focused on -1082A>G [5, 13, 25–28, 31, 34], sixteen case-control studies focused on -819T>C [5, 13, 25–32, 35, 36], and eleven case-control studies focused on -592A>C [13, 26–29, 31, 33, 35, 37]. In addition, ten publications came from ME [5, 25–28, 31, 33–36], five publications came from East Asia (EA) [13, 30, 32, 35], and three publications came from European descendants [25, 29, 37]. Moreover, the genotype frequencies in the control group in two studies of the -1082A>G polymorphism and one study of the -592A>C polymorphism deviated from HWE. Furthermore, four articles only had allele data, which resulted in the HWE assessment not being calculated [34–37]. All the related characteristics are presented in Table 2.

3.2. Quantitative Analysis

3.2.1. -1082A>G Polymorphism and BD Risk. Nine case-control studies, involving 1,042 patients and 1,389 controls, were identified on the association between the -1082A>G polymorphism and BD risk in this meta-analysis, and these are shown in Table 3. Overall, the synthetic data indicated that there was no significant association between the -1082A>G polymorphism and BD risk in the overall population for all five genetic models (G vs. A: OR = 0.94, 95%CI = 0.77–1.15, P = 0.55, I² = 52.0%; AG vs. AA: OR = 0.91, 95%CI = 0.65–1.29, P = 0.60, I² = 64.2%; GG vs. AA: OR = 0.89, 95%CI = 0.64–1.24, P = 0.50, I² = 29.2%; AG+GG vs. AA: OR = 0.91, 95%CI = 0.67–1.23, P = 0.53, I² = 58.1%; and GG vs. AA +AG: OR = 0.99, 95%CI = 0.59–1.66, P = 0.50, I² = 59.9%) (Table 3, Figure 2(a) for the G vs. A model). Moderate heterogeneity was identified in allele contrast, heterozygote model, dominant model, and recessive model. Then, metaregression analyses were conducted and they did not find any factors that might be responsible for the emergence of heterogeneity. In addition, no significant relationship was
found in the subgroup analyses based on HWE status, ethnic differences, or control design (Table 3). Cumulative analyses presented a consistent trend of negative results with publication date, except for the second case-control study by Wallace et al. [25] (Figure 2(b) for the G vs. A model). Sensitivity analyses demonstrated that no single study had a significant influence on the overall outcome (Figure 2(c) for the G vs. A model). In addition, no significant asymmetrical funnel plot for publication bias was observed among the included studies, which was also demonstrated by Egger’s test (G vs. A: \( P = 0.63 \); AG vs. AA: \( P = 0.95 \); GG vs. AA: \( P = 0.87 \); AG +GG vs. AA: \( P = 0.75 \); and GG vs. AA+AG: \( P = 0.86 \) (Figure 2(d) for the G vs. A model).

3.2.2. -819T>C Polymorphism and BD Risk. Sixteen case-control studies, involving 5,550 cases and 8,469 controls, were identified on the association between the -819T>C polymorphism and BD risk in this meta-analysis, and these are shown in Table 3. Overall, a significant association of protective effects was observed in all five genetic models (C vs. T, \( OR = 0.72, 95\% CI = 0.67-0.77, P < 0.01, I^2 = 36.6\% \); TC vs. TT, \( OR = 0.73, 95\% CI = 0.66-0.80, P < 0.01, I^2 = 23.0\% \); CC vs. TT, \( OR = 0.52, 95\% CI = 0.39-0.70, P < 0.01, I^2 = 53.7\% \); TC+CC vs. TT, \( OR = 0.67, 95\% CI = 0.61-0.71, P < 0.01, I^2 = 22.1\% \); and CC vs. TT+TC, \( OR = 0.66, 95\% CI = 0.53-0.82, P < 0.01, I^2 = 57.8\% \) (Table 3, Figure 3(a) for the C vs. T model). Notably, moderate heterogeneity was identified only in the homozygote model and the recessive model; metaregression analyses were also conducted but did not find any interfering factors that might be responsible for the emergence of heterogeneity. Furthermore, significant protective associations were also found in the subgroup of the East Asians (C vs. T, \( OR = 0.69, 95\% CI = 0.61-0.77, P < 0.01, I^2 = 45.2\% \) (Figure 3(a) for the C vs. T model); TC vs. TT, \( OR = 0.72, 95\% CI = 0.65-0.80, P < 0.01, I^2 = 0\% \); CC vs. TT, \( OR = 0.40, 95\% CI = 0.26-0.62, P < 0.01, I^2 = 72.6\% \); TC +CC vs. TT, \( OR = 0.67, 95\% CI = 0.60-0.74, P < 0.01, I^2 = 0\% \); and CC vs. TT+TC, \( OR = 0.47, 95\% CI = 0.32-0.71, P <

![Figure 1: Flow diagram of the study selection process.](image-url)
Table 2: Characteristics of included studies on IL-10 gene polymorphisms and Behcet’s disease risk.

| First author | Year | Country/region | Racial | Source of controls | Case | Control | Genotype distribution | Genotyping methods | P for HWE | NOS |
|--------------|------|----------------|--------|--------------------|------|---------|----------------------|-------------------|----------|-----|
| Wallace-1    | 2007 | UK             | Europe | HB                 | 63   | 182     | AA 27 13 59 75 48    | PCR-SSP           | 0.02     | 5   |
| Wallace-2    | 2007 | Jordan and Palestinian | ME     | HB                 | 115  | 113     | 50 50 15 46 40 27    | PCR-SSP           | <0.01    | 5   |
| Dilek        | 2009 | Turkey         | ME     | PB                 | 96   | 124     | 26 66 4 56 58 10     | PCR-SSP           | 0.35     | 8   |
| Ates         | 2010 | Turkey         | ME     | PB                 | 102  | 102     | 39 50 13 44 50 8     | ARMS-PCR          | 0.23     | 7   |
| Shahram      | 2011 | Iran           | ME     | HB                 | 147  | 140     | 58 81 8 53 75 12     | PCR-SSP           | 0.04     | 5   |
| Talatat      | 2014 | Egypt          | ME     | HB                 | 87   | 97      | 32 34 21 32 53 12     | MS-PCR            | 0.16     | 6   |
| Hu-1         | 2015 | China          | EA     | PB                 | 300  | 350     | 271 29 0 293 56 1     | PCR-RFLP          | 0.32     | 10  |
| Al-Okaily    | 2015 | Saudi Arabia   | ME     | PB                 | 61   | 211     | 14 37 10 36 159 16   | ARMS-PCR          | <0.01    | 7   |
| Barış        | 2016 | Turkey         | ME     | HB                 | 71   | 70      | 98 44 99 41           | PCR-RFLP          | NA       | 4   |
|              |      |                |        |                    |      |         |                      |                   |          |     |
| Wallace-1    | 2007 | UK             | Europe | HB                 | 63   | 182     | 7 28 44 13 67 102    | PCR-SSP           | 0.66     | 6   |
| Wallace-2    | 2007 | Jordan and Palestinian | ME     | HB                 | 115  | 113     | 11 61 43 10 43 60    | PCR-SSP           | 0.57     | 6   |
| Dilek        | 2009 | Turkey         | ME     | PB                 | 96   | 124     | 7 50 39 13 47 64     | PCR-SSP           | 0.33     | 8   |
| Ates         | 2010 | Turkey         | ME     | PB                 | 102  | 102     | 10 45 47 11 44 47    | ARMS-PCR          | 0.88     | 7   |
| Mizuki-1     | 2010 | Japan          | EA     | HB                 | 611  | 737     | 935 287 979 495      | GeneChip          | NA       | 5   |
| Mizuki-2     | 2010 | Korea          | EA     | HB                 | 119  | 140     | 184 54 194 41        | GeneChip          | NA       | 4   |
| Mizuki-3     | 2010 | Turkey         | ME     | HB                 | 1215 | 1279    | 931 1499 801 1757     | GeneChip          | NA       | 5   |
| Shahram      | 2011 | Iran           | ME     | HB                 | 147  | 140     | 12 64 71 12 57 71    | PCR-SSP           | 0.91     | 6   |
| Khairy       | 2013 | Algeria        | ME     | HB                 | 51   | 96      | 11 23 17 5 41 50     | Direct sequencing | 0.35     | 7   |
| Wu           | 2014 | China          | EA     | PB                 | 407  | 679     | 209 167 31 202 295    | Sequenom MassArray | 0.45     | 9   |
| Talatat      | 2014 | Egypt          | ME     | HB                 | 87   | 97      | 5 35 42 6 41 50      | MS-PCR            | 0.53     | 6   |
| Carapito     | 2015 | Iran           | ME     | HB                 | 552  | 341     | 376 728 255 579      | Taqman            | NA       | 5   |
| Hu-1         | 2015 | China          | EA     | PB                 | 300  | 350     | 168 126 6 146 160    | PCR-RFLP          | 0.99     | 10  |
| Hu-2         | 2015 | China          | EA     | PB                 | 418  | 1403    | 216 175 27 558 679    | PCR-RFLP          | 0.06     | 10  |
| Al-Okaily    | 2015 | Saudi Arabia   | ME     | PB                 | 61   | 211     | 12 22 27 21 102 88   | ARMS-PCR          | 0.27     | 8   |
| Yu           | 2017 | China          | EA     | PB                 | 1206 | 2475    | 661 459 86 1121 1078  | Real-time PCR     | 0.49     | 9   |
|              |      |                |        |                    |      |         |                      |                   |          |     |
| Dilek        | 2009 | Turkey         | ME     | PB                 | 96   | 124     | 7 50 39 13 47 44     | PCR-SSP           | 0.33     | 8   |
| Ates         | 2010 | Turkey         | ME     | PB                 | 102  | 102     | 10 45 47 11 44 47    | ARMS-PCR          | 0.88     | 7   |
| Mizuki-1     | 2010 | Japan          | EA     | HB                 | 611  | 737     | 935 287 979 495      | GeneChip          | NA       | 5   |
| Mizuki-2     | 2010 | Korea          | EA     | HB                 | 119  | 140     | 184 54 194 41        | GeneChip          | NA       | 4   |
| Mizuki-3     | 2010 | Turkey         | ME     | HB                 | 1215 | 1279    | 931 1499 801 1757     | GeneChip          | NA       | 5   |
0.01, $I^2 = 71.1\%$) (Table 3). In addition, the same protective effects were also observed in both the control design groups and the genotyping groups (Table 3). Cumulative analyses steadily demonstrated a significant association with all studies (Figure 3(b) for the C vs. T model). Sensitivity analysis was conducted and did not present any apparent changes in the five genetic models (Figure 3(c) for the C vs. T model). In addition, no significant asymmetrical funnel plot for publication bias was observed among the included studies, which was also demonstrated by Egger’s test (C vs. A: $P = 0.44$; TC vs. TT: $P = 0.73$; CC vs. TT: $P = 0.94$; TC +CC vs. TT: $P = 0.87$; and CC vs. TT+TC: $P = 0.79$) (Figure 3(d) for the C vs. T model).

3.2.3. -592A>C Polymorphism and BD Risk. Eleven case-control studies, involving 3,052 cases and 3,553 controls, were identified on the association between the -592A>C polymorphism and BD risk in this meta-analysis, and these are shown in Table 3. Overall, significant protective effects were observed in four genetic models (C vs. A: OR = 0.72, 95% CI = 0.57-0.91, $P = 0.01$, $I^2 = 56.5\%$; CC vs. AA: OR = 0.52, 95%CI = 0.28-0.95, $P = 0.03$, $I^2 = 61.9\%$; CA+CC vs. AA: OR = 0.53, 95%CI = 0.38-0.92, $P = 0.02$, $I^2 = 57.1\%$; and CC vs. AA+AC: OR = 0.72, 95%CI = 0.50-0.97, $P = 0.04$, $I^2 = 48.0\%$) (Table 3, Figure 4(a) for the C vs. A model). However, the results of the stratified analysis of ethnic differences, control design, and genotyping method presented a negative association. Cumulative analyses indicated that the pooled result demonstrated a significant association between the -592A>C polymorphism and BD risk when the study of Hu et al. was added in the allele contrast and the recessive model [13], or the study of Afkari et al. was added in the homozygote model and dominant models [33] (Figure 4(b) for the C vs. A model). Sensitivity analysis was also conducted, and it demonstrated a significant association without the study by Khaib et al. [29] (Figure 4(c) for the C vs. A model). In addition, no significant asymmetrical funnel plot for publication bias was observed among the included studies, which was also demonstrated by Egger’s test (C vs. A: $P = 0.72$; AC vs. AA: $P = 0.73$; CC vs. AA: $P = 0.95$; AC+CC vs. AA: $P = 0.67$; and CC vs. AA +AC: $P = 0.40$) (Figure 4(d) for the C vs. A model).

3.3. IL-10 Haplotype and BD Risk. Among the selected studies, only three studies provided enough data on the association between the IL-10 -1082A>G, -819T>C, and -592A>C haplotypes and BD risk. Three well-known haplotypes of ATA, ACC, and GCC were found and included in this meta-analysis. The haplotype frequency data were examined, and the quantitative synthesis did not demonstrate any significant associations when the ACC and GCC haplotypes were compared with the ATA haplotype (ACC vs. ATA: OR = 1.04, 95%CI = 0.80-1.35, $P = 0.78$, $I^2 = 0\%$; and GCC vs. ATA: OR = 0.80, 95%CI = 0.52-1.22, $P = 0.30$, $I^2 = 60.9\%$) (Table 4).

4. Discussion

To date, the pathogenesis and etiology of BD have not been elucidated. It is speculated that BD has characteristics of both inflammatory and autoimmune diseases and has a certain genetic susceptibility. Patients with BD have always suffered from serious complications, such as recurrent oral ulcers, genital ulcers, and uveitis. In addition, these microvascular inflammatory injuries are frequently involved in the gastrointestinal tract, central nervous system, large blood vessels, and limb joints in BD patients [12, 13]. The IL-10 gene is located on chromosome 1 at 1q31-32, occupies more than 4.7 kb of genomic DNA, and consists of five exons and four introns. These are the three most studied genetic variants: -1082A>G (rs1800896), -819T>C (rs1800871), and -592A>C (rs1800872). These polymorphisms and their haplotypes are associated with abnormal circulating levels of IL-10 and contribute to the pathophysiology of various autoimmune and inflammatory diseases. During the triggering and development of BD, many inflammatory markers have been proposed to be involved in the development of BD. IL-10 is one of the most important immunoregulatory cytokines and is mainly secreted by macrophage cells and other T helper 1 (Th1) and Th2 cells [38]. IL-10 participates in complex inflammatory and immune
| Locus     | N*  | OR   | 95% CI     | \( I^2 \) (%)^a | OR | 95% CI     | \( I^2 \) (%)^a | OR | 95% CI     | \( I^2 \) (%)^a | OR | 95% CI     | \( I^2 \) (%)^a |
|-----------|-----|------|------------|----------------|----|------------|----------------|----|------------|----------------|----|------------|----------------|
| -1082A>G  |     |      |            |                |    |            |                |    |            |                |    |            |                |
| Total     | 9   | 0.95 | 0.79-1.15  | 0.60 0.91      | 0.60 0.62 0.89 | 0.50 0.29 0.91 | 0.53 0.51 0.99 | 0.59-1.66 0.50 59.9 |
| HWE—yes  | 4   | 1.04 | 0.72-1.54  | 0.83 0.87      | 0.99 0.81 1.45 | 0.19 0.01 1.05 | 0.87 0.79 1.30 | 0.61-2.77 0.59 41.6 |
| HWE—no   | 4   | 0.85 | 0.70-1.03  | 0.09 0.99      | 0.36 0.06 0.68 | 0.07 1.58 0.81 | 0.61-1.07 0.13 0.83 | 0.42-1.63 0.95 66.4 |
| Ethnicity |     |      |            |                |    |            |                |    |            |                |    |            |                |
| Europe   | 1   | 0.72 | 0.48-1.09  | 0.12 NA 0.67   | 0.23 NA 0.59 | 0.18 NA 0.64 | 0.36-1.15 0.14 NA 0.37     |
| ME       | 7   | 1.05 | 0.90-1.22  | 0.55 7.5 1.05  | 0.79 61.1 1.00 | 1.00 38.3 1.06 | 0.77-1.45 0.72 46.3 1.07 | 0.57-2.04 0.83 69.0 |
| EA       | 1   | 0.56 | 0.35-0.89  | 0.01 NA 0.56   | 0.02 NA 0.36 | 0.01-0.88 | 0.53 NA 0.55 | 0.34-0.89 0.01 NA 0.20 |
| Design   |     |      |            |                |    |            |                |    |            |                |    |            |                |
| HB       | 5   | 0.89 | 0.74-1.07  | 0.21 4.0 0.87  | 0.36 0.74 | 0.28 42.9 0.84 | 0.64-1.09 0.19 0.83 | 0.42-1.63 0.59 67.7 |
| PB       | 4   | 1.02 | 0.70-1.47  | 0.93 68.3 0.98 | 0.96 82.1 1.37 | 1.00 38.3 1.06 | 0.77-1.45 0.72 46.3 1.07 | 0.57-2.04 0.83 69.0 |
| -819T>C  |     |      |            |                |    |            |                |    |            |                |    |            |                |
| Total     | 16  | 0.72 | 0.68-0.86  | <0.01 0.38 0.73 | 0.06-0.80 | <0.01 23.0 0.52 | 0.39-0.70 0.01 53.7 0.67 | 0.61-0.71 0.21 0.66 | 0.53-0.82 0.01 57.8 |
| Ethnicity |     |      |            |                |    |            |                |    |            |                |    |            |                |
| Europe   | 2   | 0.67 | 0.33-1.36  | 0.27 78.6 0.46 | 0.16-1.37 | 0.17 49.3 0.36 | 0.07-1.83 0.22 77.0 0.41 | 0.11-1.58 0.20 70.1 0.70 | 0.33-1.47 0.35 65.0 |
| ME       | 8   | 0.79 | 0.72-0.86  | <0.01 0.92     | 0.55-1.52 | 0.74 40.8 0.78 | 0.53-1.14 0.20 0.84 | 0.59-1.21 0.36 7.4 0.81 | 0.65-1.01 0.06 5.2 |
| EA       | 6   | 0.68 | 0.63-0.73  | <0.01 34.1 0.72 | 0.06-0.80 | <0.01 0.40 | 0.26-0.62 0.01 72.6 0.67 | 0.60-0.74 <0.01 0.47 | 0.32-0.71 <0.01 71.1 |
| Design   |     |      |            |                |    |            |                |    |            |                |    |            |                |
| HB       | 8   | 0.84 | 0.66-0.92  | <0.01 36.7 0.92 | 0.56-1.49 | 0.73 0.74 | 0.46-1.20 0.23 0.83 | 0.52-1.21 0.42 0.81 | 0.62-1.04 0.10 10.7 |
| PB       | 8   | 0.71 | 0.63-0.80  | <0.01 45.7 0.72 | 0.65-0.80 | <0.01 39.0 0.46 | 0.32-0.87 <0.01 65.4 0.66 | 0.56-0.78 <0.01 42.3 0.59 | 0.44-0.80 <0.01 64.1 |
| Genotyping |     |      |            |                |    |            |                |    |            |                |    |            |                |
| PCR      | 9   | 0.76 | 0.66-0.89  | <0.01 42.3 0.72 | 0.61-0.84 0.37-0.89 | 0.01 59.8 0.64 | 0.55-0.75 <0.01 3.8 0.69 | 0.50-0.94 0.02 66.6 |
| Locus          | N* | OR   | 95% CI | P   | $I^2$ (%)$^a$ | OR   | 95% CI | P   | $I^2$ (%)$^a$ | OR   | 95% CI | P   | $I^2$ (%)$^a$ | OR   | 95% CI | P   |
|---------------|----|------|--------|-----|--------------|------|--------|-----|--------------|------|--------|-----|--------------|------|--------|-----|
| Other         | 7  | 0.71 | 0.65-  | 0.01 | <0.01        | 43.2 | 0.73   | 0.01 | 47.9         | 0.47 | 0.32-  | <0.01 | 50.2         | 0.67 | 0.50-  | <0.01 |
| -592A>C (rs1800872) C vs. A AC vs. AA CC vs. AA AC+CC vs. AA CC vs. AA+AC | | | | | | | | | | | | | | | |
| Total         | 11 | 0.71 | 0.63-  | <0.01 | 45.4         | 0.64 | 0.40- | 0.06 | 59.2         | 0.52 | 0.28-  | 0.03 | 61.9         | 0.59 | 0.38-  | 0.02 |
| HWE—yes      | 6  | 0.75 | 0.58-  | 0.02 | 60.9         | 0.71 | 0.43- | 0.20 | 59.6         | 0.54 | 0.28-  | 0.07 | 67.8         | 0.65 | 0.40-  | 0.08 |
| HWE—no       | 1  | 0.53 | 0.29-  | 0.03 | NA           | 0.33 | 0.14- | 0.01 | NA           | 0.33 | 0.05-  | 0.24 | NA           | 0.33 | 0.14- | 0.01 |
| Ethnicity     |    |      |        |      |              |      |        |      |              |      |        |      |              |      |        |      |
| Europe        | 2  | 0.63 | 0.37-  | 0.10 | 73.7         | 0.25 | 0.08- | 0.02 | NA           | 0.15 | 0.05-  | <0.01 | NA           | 0.20 | 0.07-  | 0.01 |
| ME            | 6  | 0.77 | 0.69-  | <0.01 | 7.6          | 0.77 | 0.39- | 0.45 | 65.7         | 0.82 | 0.53-  | 0.37 | 0          | 0.74 | 0.42-  | 0.30 |
| EA            | 3  | 0.60 | 0.53-  | <0.01 | 0            | 0.57 | 0.41- | <0.01 | NA           | 0.23 | 0.11-  | <0.01 | NA           | 0.51 | 0.37-  | <0.01 |
| Design        |    |      |        |      |              |      |        |      |              |      |        |      |              |      |        |      |
| HB            | 5  | 0.70 | 0.64-  | <0.01 | 39.1         | 0.61 | 0.18- | 0.43 | 76.6         | 0.79 | 0.36-  | 0.55 | 8.4          | 0.58 | 0.18-  | 0.36 |
| PB            | 6  | 0.73 | 0.59-  | 0.01 | 57.2         | 0.65 | 0.37- | 0.14 | 61.6         | 0.48 | 0.23-  | 0.05 | 69.7         | 0.60 | 0.35-  | 0.06 |
| Genotyping    |    |      |        |      |              |      |        |      |              |      |        |      |              |      |        |      |
| PCR           | 7  | 0.77 | 0.64-  | 0.01 | 46.1         | 0.70 | 0.43- | 0.16 | 60.2         | 0.62 | 0.34-  | 0.11 | 56.2         | 0.66 | 0.43-  | 0.05 |
| Other         | 4  | 0.65 | 0.56-  | <0.01 | 47.4         | 0.25 | 0.08- | 0.02 | NA           | 0.15 | 0.05-  | <0.01 | NA           | 0.20 | 0.07-  | 0.01 |

$^a$Numbers of comparisons. $^b$Test for heterogeneity. ME: Middle East; EA: East Asia; PB: population based; HB: healthy-based control/normal control.
| Study ID            | OR (95% CI)   | % weight |
|---------------------|---------------|----------|
| Europe              |               |          |
| Wallace-1 (2007)    | 0.72 (0.48, 1.09) | 11.07    |
| Subtotal ($I^2 = .%, p = .$) | 0.72 (0.48, 1.09) | 11.07    |
| ME                  |               |          |
| Wallace-2 (2007)    | 0.75 (0.51, 1.09) | 12.11    |
| Dilek (2009)        | 1.37 (0.92, 2.03) | 11.60    |
| Ates (2010)         | 1.24 (0.83, 1.87) | 11.21    |
| Shahram (2011)      | 0.90 (0.64, 1.27) | 13.24    |
| Talaat (2014)       | 1.18 (0.78, 1.79) | 11.00    |
| Al-Okaily (2015)    | 1.06 (0.71, 1.59) | 11.34    |
| Baris (2016)        | 1.08 (0.65, 1.80) | 8.64     |
| Subtotal ($I^2 = 7.5\%, p = 0.371$) | 1.05 (0.90, 1.23) | 79.14    |
| EA                  |               |          |
| Hu-1 (2015)         | 0.56 (0.35, 0.89) | 9.79     |
| Subtotal ($I^2 = .%, p = .$) | 0.56 (0.35, 0.89) | 9.79     |
| Overall ($I^2 = 46.1\%, p = 0.062$) | 0.95 (0.79, 1.15) | 100.00   |
| Note: weights are from random effects analysis |          |          |

Note: weights are from random effects analysis

(a) Figure 2: Continued.

(b) Figure 2: Continued.
processes by promoting the widespread suppression of immune effects and the abnormal circulating level of IL-10 which has been associated with an increased risk for the development of BD.

In 2007, Wallace et al. published the first case-control study of the UK population and suggested that subjects with the -1082AA genotype were weakly associated with BD risk in the general population (OR = 1.4; 95% CI = 1.1 - 1.9, P = 0.04), and the -819T allele also indicated an increased BD risk (OR = 1.5; 95% CI = 1.1 - 2.0, P = 0.02). In subsequent years, an increasing number of case-control studies have been conducted to explore the association between IL-10 polymorphisms and BD susceptibility; however, the results were inconsistent and confusing. In 2013, Liang et al. published a meta-analysis on IL-10 gene polymorphisms and BD susceptibility and suggested that the IL-10 -1082A>G, -819T>C, and -592A>C polymorphisms were indeed associated with BD susceptibility [17]. However, the results were only based on two, five, and four case-controls on the IL-10 -1082A>G, -819T>C, and -592A>C loci, respectively, and the sample sizes were small as well. In 2015, Jung et al. conducted a meta-analysis on IL-10 polymorphisms and vasculitis susceptibility and reported a significant association between the IL-10 -819T>C and -592A>C polymorphisms and BD susceptibility in the stratified analysis based on only one genetic model (allele contrast). In addition, the two previous meta-analyses did not report any influence from subgroup factors, such as HWE status, ethnic
### Study ID | OR (95% CI) | % weight
---|---|---
Europe
Wallace-1 (2007) | 0.95 (0.62, 1.45) | 1.35
Khaib (2013) | 0.46 (0.28, 0.76) | 1.34
Subtotal ($I^2 = 78.6\%, p = 0.031$) | 0.70 (0.51, 0.97) | 2.69
ME
Wallace-2 (2007) | 0.68 (0.46, 1.02) | 1.84
Dilek (2009) | 0.83 (0.56, 1.25) | 1.58
Ates (2010) | 1.02 (0.67, 1.55) | 1.36
Mizuki-3 (2010) | 0.73 (0.65, 0.83) | 20.34
Shahram (2011) | 0.95 (0.67, 1.36) | 1.89
Talaat (2014) | 0.81 (0.52, 1.27) | 1.31
Carapito (2015) | 0.85 (0.70, 1.03) | 6.97
Al-Okaily (2015) | 0.86 (0.56, 1.30) | 1.46
Subtotal ($I^2 = 0.0\%, p = 0.614$) | 0.79 (0.72, 0.86) | 36.74
EA
Mizuki-1 (2010) | 0.61 (0.51, 0.72) | 10.65
Mizuki-2 (2010) | 0.66 (0.45, 0.98) | 1.89
Wu (2014) | 0.77 (0.63, 0.93) | 7.67
Hu-1 (2015) | 0.54 (0.43, 0.70) | 5.47
Hu-2 (2015) | 0.67 (0.56, 0.79) | 10.45
Yu (2017) | 0.72 (0.65, 0.80) | 24.45
Subtotal ($I^2 = 34.1\%, p = 0.180$) | 0.68 (0.63, 0.73) | 60.57
Overall ($I^2 = 38.6\%, p = 0.058$) | 0.72 (0.68, 0.76) | 100.00

(a)

| Study ID | OR (95% CI) |
|---|---|
| Wallace-1 (2007) | 0.95 (0.62, 1.45) |
| Wallace-2 (2007) | 0.80 (0.60, 1.06) |
| Dilek (2009) | 0.81 (0.64, 1.02) |
| Ates (2010) | 0.86 (0.70, 1.05) |
| Mizuki-1 (2010) | 0.70 (0.61, 0.80) |
| Mizuki-2 (2010) | 0.69 (0.61, 0.79) |
| Mizuki-3 (2010) | 0.72 (0.66, 0.78) |
| Shahram (2011) | 0.73 (0.67, 0.79) |
| Khaib (2013) | 0.72 (0.66, 0.78) |
| Wu (2014) | 0.73 (0.67, 0.78) |
| Talaat (2014) | 0.73 (0.68, 0.78) |
| Carapito (2015) | 0.74 (0.69, 0.80) |
| Hu-1 (2015) | 0.73 (0.68, 0.78) |
| Hu-2 (2015) | 0.72 (0.67, 0.76) |
| Al-Okaily (2015) | 0.72 (0.68, 0.77) |
| Yu (2017) | 0.72 (0.68, 0.76) |

(b)

Figure 3: Continued.
Today, we comprehensively summarized the current evidence and conduct this meta-analysis to explore the precise relationships between IL-10 polymorphisms and BD susceptibility with more stratified analysis. Overall, the pooled results demonstrated a significant association between the -819T>C polymorphism and BD susceptibility in all five genetic models, suggesting that the -819T>C polymorphism may decrease the risk of BD from 48% to 28%. Similarly, decreased BD risk was also observed in the subgroup analysis of the ethnic differences, control design, and genotyping method groups. In the -592A>C polymorphism, the pooled analysis of all five genetic models demonstrated that the mutation of -592A>C lowered the risk of developing BD from 48 to 29%. Moreover, similar results were also observed in many genetic models in the subgroup analysis of HWE status, ethnic differences, control design, and genotyping method groups. Regarding the -1082A>G polymorphism, no significant association was observed for BD risk, except for a few scattered cases of decreased BD risk in the G allele and the AG genotype in the EA population.

Figure 3: Statistical analysis of the association between IL-10 -819T>C polymorphism and BD risk in the C vs. T model. (a) ORs and 95% CIs; (b) cumulative analysis; (c) sensitivity analysis; (d) publication bias.
| Study ID          | OR (95% CI)    | % weight |
|-------------------|----------------|----------|
| **ME**            |                |          |
| Dilek (2009)      | 0.83 (0.56, 1.25) | 6.40     |
| Ates (2010)       | 1.02 (0.67, 1.55) | 6.17     |
| Shahram (2011)    | 0.92 (0.64, 1.32) | 7.63     |
| Al-Okaily (2015)  | 0.86 (0.56, 1.30) | 6.13     |
| Afkari (2018)     | 0.53 (0.29, 0.95) | 3.53     |
| Mizuki-3 (2010)   | 0.73 (0.65, 0.83) | 19.41    |
| Subtotal (I² = 7.6%, p = 0.368) | 0.78 (0.69, 0.88) | 49.27    |
| **Europe**        |                |          |
| Khaib (2013)      | 0.46 (0.28, 0.76) | 4.56     |
| Montes-Cano (2013)| 0.80 (0.62, 1.04) | 11.52    |
| Subtotal (I² = 73.7%, p = 0.051) | 0.63 (0.37, 1.09) | 16.08    |
| **EA**            |                |          |
| Hu-1 (2015)       | 0.56 (0.44, 0.72) | 11.96    |
| Mizuki-1 (2010)   | 0.61 (0.51, 0.72) | 16.05    |
| Mizuki-2 (2010)   | 0.66 (0.45, 0.98) | 6.64     |
| Subtotal (I² = 0.0%, p = 0.765) | 0.60 (0.53, 0.68) | 34.65    |
| Overall (I² = 45.4%, p = 0.050) | 0.71 (0.63, 0.80) | 100.00   |

Note: weights are from random effects analysis

(a)

(b)

Figure 4: Continued.
Previous studies had demonstrated that these three polymorphisms were proposed to affect the transcription efficiency and expression of the IL-10 gene [41]. More than 70% of the individual variability in human IL-10 production has been attributed to genetic variation, which could help to predict patient susceptibility to the disease as well as the severity and progression of the disease [42–44]. For the -1082A>G polymorphism, the A allele demonstrated a higher binding affinity to the transcription factor PU.1, resulting in decreased transcriptional activity and lower expression level of IL-10 [45]. In addition, the -819T>C genotype is also a functional polymorphism that could modify NF binding and result in higher levels of IL-10 production with the -819 CC genotype than with the -819 TC and TT.

**Table 4:** Meta-analysis of the IL-10 -1082A>G, -819T>C and -592A>C haplotype and BD risk.

| Contrast | OR     | 95% CI | P   | I²   | Egger’s test |
|----------|--------|--------|-----|------|--------------|
| ACC vs. ATA | Total | 1.04   | 0.80-1.35 | 0.78 | 0             | 0.11        |
| Turkey    | 1.12   | 0.81-1.57 | 0.45 | 0    |               |             |
| Iran      | 0.92   | 0.60-1.39 | 0.68 | NA   |               |             |
| GCC vs. ATA | Total | 0.80   | 0.52-1.22 | 0.30 | 0.60-1.39 | 0.41        |
| Turkey    | 0.67   | 0.40-1.13 | 0.14 | 55.9 |               |             |
| Iran      | 1.07   | 0.71-1.61 | 0.74 | NA   |               |             |

NA: not available.
genotypes [46]. Furthermore, the functional analysis indicated that the nucleotide mutation from cytosine (C) to adenine (A) would reduce the inhibitory effect of the transcription factor Sp1/Sp3 complex and increase the expression of IL-10 [47]. Regarding haplotype, no significant difference among the main haplotypes was observed. Due to the small sample sizes and the limited number of studies, this result requires further confirmation before being taken as fact.

To the best of our knowledge, this report describes the most comprehensive meta-analysis on the issue to date. Some advances were demonstrated in this meta-analysis. First, most case-control studies published on the main three polymorphisms were considered, which would increase the statistical power and help to increase understanding of the association between IL-10 gene polymorphisms and BD risk. Second, a stratified analysis based on HWE status, ethnic differences, control design, and genotyping methods was conducted to explore their potential relationships. Third, a more scientific retrieval strategy and statistical methodology were used, including cumulative analyses, sensitivity analyses, and haplotype analyses.

Of course, there were still some inherent limitations that should be addressed in this meta-analysis. First, there were only 7, 12, and 7 case-control studies on IL-10 -1082A>G, -819T>C, and -592A>C loci, respectively, with complete information on the wild homozygotes, heterozygotes, and mutant homozygotes; the others only had the allele data in this meta-analysis. Therefore, the synthetic results and subgroup analysis could not reveal the real association between IL-10 gene polymorphisms and BD susceptibility with limited sample size. Second, most subjects came from the ME, EA, and Europe; therefore, the results of this systematic review and meta-analysis cannot represent all ethnic populations, and the conclusions are only applicable to these ethnicities. Third, other potential factors, such as living habits, mental stress, age, and immunological disarrangement, were not assessed, as sufficient data were not available. Fourth, this meta-analysis is based on published studies; therefore, potential publication bias may be present, even if the tests utilized in this meta-analysis did not find it. Fifth, moderate or high heterogeneity could be observed in these polymorphism sites. To the best of our knowledge, clinical heterogeneity (sometimes called clinical diversity), methodological heterogeneity (sometimes called methodological diversity), and statistical heterogeneity were the three most common sources. In this meta-analysis, the severity of disease, control design, personal habits, and ethnic differences may be the potential factors that contribute to the existing heterogeneity. These above factors would lead to a deviation in the authenticity and reliability of our results. Fortunately, the heterogeneity was partly alleviated in the stratified analysis based on ethnic differences and control design. In terms of the former, the heterogeneity has obviously been relieved in the subgroup analysis of the Middle East populations in -819T>C and -592A>C polymorphism loci. Given the control design, the degree of heterogeneity has decreased in these studies with healthy-based controls in some genetic models of the -1082A>G and -819T>C polymorphisms.

5. Conclusions

The current evidence indicates that there is a potential association between IL-10 gene polymorphisms and BD susceptibility, especially the -819T>C and -592A>C polymorphisms. In future studies, more case-control studies with larger sample sizes and different ethnicities are needed to verify these conclusions.

Data Availability

The raw data supporting this meta-analysis are from previously reported studies and datasets. All included data are also available from the corresponding author upon request.

Disclosure

The funders had no roles in the study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Conflicts of Interest

The authors declare that they have no competing interests.

Authors’ Contributions

NYM and LXF designed and wrote the manuscript. NYM and HYY searched the databases and extracted the data. HZZ and CJW analyzed the data. LXF edited and prepared the manuscript for submission. All authors read and approved the final manuscript. Xue-Feng Li and Zhi-Zheng Huang contributed equally to this work.

Acknowledgments

This study was supported by the Foundations of Hubei Province Health and Family Planning Scientific Research Project (No. WJ2019F135) and Taihe Hospital (2016Z13).

Supplementary Materials

Search strategies for the online databases. (Supplementary Materials)

References

[1] M. Takeuchi, D. L. Kastner, and E. F. Remmers, “The immunogenetics of Behcet’s disease: a comprehensive review,” Journal of Autoimmunity, vol. 64, pp. 137–148, 2015.
[2] T. Sakane, M. Takeno, N. Suzuki, and G. Inaba, “Behcet’s disease,” The New England Journal of Medicine, vol. 341, no. 17, pp. 1284–1291, 1999.
[3] H. Yazici, E. Seyahi, G. Hatemi, and Y. Yazici, “Behçet syndrome: a contemporary view,” Nature Reviews Rheumatology, vol. 14, no. 2, pp. 107–119, 2018.
[4] Disease ISGfBs, “Criteria for diagnosis of Behcet’s disease. International Study Group for Behcet’s Disease,” Lancet, vol. 335, no. 8697, pp. 1078–1080, 1990.
[5] R. M. Talaat, M. E. Ashour, I. H. Bassyouni, and A. A. Raouf, “Polymorphisms of interleukin 6 and interleukin 10 in
Egyptian people with Behçet’s disease,” *Immunobiology*, vol. 219, no. 8, pp. 573–582, 2014.

[6] G. Azizlerli, A. Akdağ Köse, R. Sarıca et al., “Prevalence of Behçet’s disease in Istanbul, Turkey,” *International Journal of Dermatology*, vol. 42, no. 10, pp. 803–806, 2003.

[7] K. T. Calamia, F. C. Wilson, M. Icen, C. S. Crowson, S. E. Gabriel, and H. M. Kremer, “Epidemiology and clinical characteristics of Behçet’s disease in the US: a population-based study,” *Arthritis and Rheumatism*, vol. 61, no. 5, pp. 600–604, 2009.

[8] Y. H. Lin, T. Y. Tai, C. Y. Pu, D. K. Hwang, Y. M. Chung, and Y. J. Chou, “Epidemiology of Behçet’s disease in Taiwan: a hospital-based epidemiological survey,” *Clinical and Experimental Rheumatology*, vol. 35, pp. 51–54, 2017.

[9] M. Zhang et al., “The prevalence of Behçet’s disease in the north of Jordan: a hospital-based epidemiological survey,” *Clinical and Experimental Rheumatology*, vol. 21, no. 12, pp. 2139–2145, 2018.

[10] G. Cheng, “Role of interleukin 10 transcriptional regulation in inflammation and autoimmune disease,” *Critical Reviews in Immunology*, vol. 32, no. 1, pp. 23–63, 2012.

[11] J. Hu, S. Hou, X. Zhu et al., “Interleukin-10 gene polymorphisms are associated with Behçet’s disease but not with Vogt-Koyanagi-Harada syndrome in the Chinese Han population,” *Molecular Vision*, vol. 21, pp. 589–603, 2015.

[12] J. Y. Yoon, Y. Lee, S. L. Yu et al., “Ablation expression of interleukin-10 and activation-induced cytidine deaminase in B cells from patients with Behçet’s disease,” *Biomedical Reports*, vol. 7, no. 6, pp. 520–526, 2017.

[13] S. Alipour, M. Nouri, A. Khabbaz et al., “Hypermethylation of IL-10 gene is responsible for its low mRNA expression in Behçet’s disease,” *Journal of Cellular Biochemistry*, vol. 119, no. 8, pp. 6614–6622, 2018.

[14] E. F. Remmers, F. Cosan, Y. Kirino et al., “Genome-wide association study identifies variants in the MHC class I, IL10, and IL23R-IL12RB2 regions associated with Behçet’s disease,” *Nature Genetics*, vol. 42, no. 8, pp. 698–702, 2010.

[15] Y. Liang, W. D. Xu, M. Zhang et al., “Meta-analysis of association between cytokine gene polymorphisms and Behçet’s disease risk,” *International Journal of Rheumatic Diseases*, vol. 16, no. 6, pp. 616–624, 2013.

[16] D. Moher, A. Liberati, J. Tetzlaff, D. G. Altman, and PRISMA Group, “Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement,” *Journal of Clinical Epidemiology*, vol. 62, no. 10, pp. 1006–1012, 2009.

[17] Y. M. Niu, H. Weng, C. Zhang et al., “Systematic review by multivariate meta-analyses on the possible role of tumor necrosis factor-α gene polymorphisms in association with ischemic stroke,” *Neuromolecular Medicine*, vol. 17, no. 4, pp. 373–384, 2015.

[18] T. B. Huedo-Medina, J. Sánchez-Meca, F. Marin-Martínez, and J. Botella, “Assessing heterogeneity in meta-analysis: Q statistic or I² index?,” *Psychological Methods*, vol. 11, no. 2, pp. 193–206, 2006.

[19] N. Mantel and W. Haenszel, “Statistical aspects of the analysis of data from retrospective studies of disease,” *Journal of the National Cancer Institute*, vol. 22, no. 4, pp. 719–748, 1959.

[20] R. DerSimonian, “Meta-analysis in the design and monitoring of clinical trials,” *Statistics in Medicine*, vol. 15, no. 12, pp. 1237–1248, 1996.

[21] M. Egger, G. D. Smith, M. Schneider, and C. Minder, “Bias in meta-analysis detected by a simple, graphical test,” *BMJ*, vol. 315, no. 7109, pp. 629–634, 1997.

[22] C. B. Begg and M. Mazumdar, “Operating characteristics of a rank correlation test for publication bias,” *Biometrics*, vol. 50, no. 4, pp. 1088–1101, 1994.

[23] G. R. Wallace, E. Kondetis, R. W. Vaughan et al., “IL-10 genotype analysis in patients with Behçet’s disease,” *Human Immunology*, vol. 68, no. 2, pp. 122–127, 2007.

[24] K. Dilek, A. A. Özçimen, F. Cosan et al., “Cytokine gene polymorphisms in Behçet’s disease and their association with clinical and laboratory findings,” *Clinical and Experimental Rheumatology*, vol. 27, pp. S73–S78, 2009.

[25] O. Ateş, L. Dalyan, G. Hatemi, V. Hamuryudan, and A. Topal-Sarıkaya, “Analyses of functional IL10 and TNF-α genotypes in Behçet’s syndrome,” *Molecular Biology Reports*, vol. 37, no. 7, pp. 3637–3641, 2010.

[26] F. Shahram, E. Nikoopour, N. Rezaei et al., “Association of interleukin-2, interleukin-4 and transforming growth factor-beta gene polymorphisms with Behçet’s disease,” *Clinical and Experimental Rheumatology*, vol. 29, pp. S28–S31, 2011.

[27] O. Dilek, A. A. Özçimen, F. Cosan et al., “Cytokine gene polymorphisms in Behçet’s disease and their association with clinical and laboratory findings,” *Clinical and Experimental Rheumatology*, vol. 29, pp. S28–S31, 2011.

[28] Z. Wu, W. Zheng, J. Xu et al., “IL10 polymorphisms associated with Behçet’s disease in Chinese Han,” *Human Immunology*, vol. 75, no. 3, pp. 271–276, 2014.

[29] M. Arfin, F. Al-Okaïly, S. Al-Rashidi, M. Al-Balawi, and A. Al Asmari, “Inflammation-related cytokine gene polymorphisms in Behcet&ccedil;ete&amp;#8217;rosquo;s disease,” *Journal of Inflammation Research*, vol. 8, pp. 173–180, 2015.

[30] H. Yu, M. Zheng, L. Zhang et al., “Identification of susceptibility SNPs in IL10 and IL23R-IL12RB2 SNPs with Behçet’s disease risk in Western Algeria,” *Frontiers in Immunology*, vol. 4, 2013.

[31] Z. Wu, W. Zheng, J. Xu et al., “IL10 polymorphisms associated with Behçet’s disease in Chinese Han,” *Human Immunology*, vol. 75, no. 3, pp. 271–276, 2014.

[32] M. Arfin, F. Al-Okaïly, S. Al-Rashidi, M. Al-Balawi, and A. Al Asmari, “Inflammation-related cytokine gene polymorphisms in Behcet&amp;#8217;rosquo;s disease,” *Journal of Inflammation Research*, vol. 8, pp. 173–180, 2015.

[33] H. Yu, M. Zheng, L. Zhang et al., “Identification of susceptibility SNPs in IL10 and IL23R-IL12RB2 for Behçet’s disease in Han Chinese,” *The Journal of Allergy and Clinical Immunology*, vol. 139, no. 2, pp. 621–627, 2017.

[34] B. Afkari, Z. Babaloo, S. Dolati et al., “Molecular analysis of interleukin-10 gene polymorphisms in patients with Behçet’s disease,” *Immunology Letters*, vol. 194, pp. 56–61, 2018.

[35] B. Afkari, Z. Babaloo, S. Dolati et al., “Molecular analysis of interleukin-10 gene polymorphisms in patients with Behçet’s disease,” *Immunology Letters*, vol. 194, pp. 56–61, 2018.

[36] S. Barış, Ö. Akyürek, A. Dursun, and M. Akyol, “The impact of the IL-1β, IL-1Ra, IL-2, IL-6 and IL-10 gene polymorphisms on the development of Behçet’s disease and their association with the phenotype,” *Medicina Clinica*, vol. 146, no. 9, pp. 379–383, 2016.

[37] N. Mizuki, A. Meguro, M. Ota et al., “Genome-wide association studies identify IL23R-IL12RB2 and IL10 as Behçet’s disease susceptibility loci,” *Nature Genetics*, vol. 42, no. 8, pp. 703–706, 2010.

[38] R. Carapito, F. Shahram, S. Michel et al., “On the genetics of the silk route: association analysis of HLA, IL10, and IL23R-IL12RB2 regions with Behçet’s disease in an Iranian population,” *Immunogenetics*, vol. 67, no. 5-6, pp. 289–293, 2015.
[37] M. Montes-Cano, M. Conde-Jaldón, J. García-Lozano et al., “HLA and non-HLA genes in Behçet’s disease: a multicentric study in the Spanish population,” Arthritis Research & Therapy, vol. 15, no. 5, p. R145, 2013.

[38] J. Trifunović, L. Miller, Z. Debeljak, and V. Horvat, “Pathologic patterns of interleukin 10 expression—a review,” Biochimia Medica, vol. 25, no. 1, pp. 36–48, 2015.

[39] E. Shahriyari, L. Vahedi, N. Roshanipour, M. A. Jafarabadi, A. Khameh, and M. G. Laleh, “Exploring the association of IL-10 polymorphisms in Behcet’s disease: a systematic review and meta-analysis,” Journal of Inflammation, vol. 16, no. 1, 2019.

[40] Y. H. Lee and G. G. Song, “Meta-analysis of associations between interleukin-10 polymorphisms and susceptibility to Behcet’s disease,” Immunologic Research, vol. 67, no. 4-5, pp. 424–431, 2019.

[41] D. M. Turner, D. M. Williams, D. Sankaran, M. Lazarus, P. J. Sinnott, and I. V. Hutchinson, “An investigation of polymorphism in the interleukin-10 gene promoter,” European Journal of Immunogenetics, vol. 24, no. 1, pp. 1–8, 1997.

[42] Y. Chenjiao, F. Zili, C. Haibin et al., “IL-10 promoter polymorphisms affect IL-10 production and associate with susceptibility to acute myeloid leukemia,” Pharmazie, vol. 68, no. 3, pp. 201–206, 2013.

[43] C. A. Naranjo-Galvis, A. de-la-Torre, L. E. Mantilla-Muriel et al., “Genetic polymorphisms in cytokine genes in Colombian patients with ocular toxoplasmosis,” Infection and Immunity, vol. 86, no. 4, 2018.

[44] C. Guo, L. Wen, J. K. Song et al., “Significant association between interleukin-10 gene polymorphisms and cervical cancer risk: a meta-analysis,” Oncotarget, vol. 9, no. 15, pp. 12365–12375, 2018.

[45] E. Reuss, R. Fimmers, A. Kruger, C. Becker, C. Rittner, and T. Höhler, “Differential regulation of interleukin-10 production by genetic and environmental factors—a twin study,” Genes and Immunity, vol. 3, no. 7, pp. 407–413, 2002.

[46] A. Salhi, V. Rodrigues Jr., F. Santoro et al., “Immunological and genetic evidence for a crucial role of IL-10 in cutaneous lesions in humans infected with Leishmania braziliensis,” Journal of Immunology, vol. 180, no. 9, pp. 6139–6148, 2008.

[47] J. W. Steinke, E. Barekzi, J. Hagman, and L. Borish, “Functional analysis of -571 IL-10 promoter polymorphism reveals a repressor element controlled by sp1,” Journal of Immunology, vol. 173, no. 5, pp. 3215–3222, 2004.